Prospective carriers of 223Ra for targeted alpha particle therapy
- 235 Downloads
We report here on basic aspects that have to be addressed in TAT systems and describe our experiments with prospective carriers of 223Ra intended for bone therapy based on hydroxyapatite nanoparticles. Preparation, in vitro stability tests are described. Labelling yields were ranging between 60–99 % depending on the reaction conditions. Preliminary static stability tests of successfully 223Ra-labelled hydroxyapatite nanoparticles were performed in a physiological saline and showed relatively low activity washout within 24 h (<5 % of total sample activity).
Keywords223Ra Radium Hydroxyapatite Carriers Targeted alpha therapy TAT
This work was partially supported by the Ministry of Education Youth and Sports of the Czech Republic, grant No.: LK21310, Technological Agency of the Czech Republic Grant No.: TA03010027 and Czech Technical University Grant No.: SGS14/084/OHK4/1D/14.
- 1.European Pharmacopoeia (2014) European medicine agency, London. http://www.ema.europa.eu. Accessed 25 May 2014
- 6.Blower PJ, Green M, Jaureghi-Osoroko M, Torres Martin de Morales R, Williamson P (2011) PCT WO 2011/151631 A1Google Scholar
- 8.Ziegler JF (2008) SRIM-2008 code, http://www.srim.org. Accessed 25 May 2014